The Non-Alcoholic Steatohepatitis Biomarkers Market is seeing strong expansion as rising awareness of fatty liver conditions increases interest in better diagnostic solutions. According to MRFR, the market was valued at USD 0.15 billion in 2024 and is expected to reach USD 1.94 billion by 2035, growing at a 26.19% CAGR.

Modern biomarker research is moving beyond conventional measurements toward more detailed biological indicators of liver inflammation and fibrosis. Serum-based testing, molecular analysis, and multi-omics techniques are helping researchers investigate diagnostic markers that could make disease assessment more convenient and less invasive.

Biomarkers are increasingly relevant across pharmaceutical research, clinical trials, diagnostic services, and academic studies. Their ability to support disease staging, patient selection, and monitoring makes them valuable for pharmaceutical companies, CROs, diagnostic centres, hospitals, and research organizations.

North America remains the largest market, while Asia-Pacific is expected to experience faster development as awareness, healthcare investment, and research capabilities improve. Growing attention to obesity, metabolic health, and liver disease is also supporting demand for advanced diagnostic technologies across regions.

Significant opportunities remain in blood-based biomarker panels, imaging-linked biomarkers, and technologies designed for early disease identification. As regulatory pathways and clinical validation frameworks develop, companies that can deliver accurate, scalable, and non-invasive solutions may find expanding opportunities in the NASH diagnostics ecosystem.